Based on the key indicators related to Aclaris Therapeutics' liquidity, profitability, solvency, and operating efficiency, Aclaris Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December. At this time, Aclaris Therapeutics' Non Currrent Assets Other are comparatively stable compared to the past year. Long Term Investments is likely to gain to about 65.9 M in 2024, whereas Other Current Liabilities is likely to drop slightly above 2.1 M in 2024. Key indicators impacting Aclaris Therapeutics' financial strength include:
Investors should never underestimate Aclaris Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Aclaris Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Aclaris Therapeutics.
Net Income
(92.91 Million)
Aclaris
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
End Period Cash Flow
Change To Liabilities
Sale Purchase Of Stock
Investments
Net Borrowings
Stock Based Compensation
Total Cashflows From Investing Activities
Change To Operating Activities
Total Cash From Financing Activities
Change To Netincome
Dividends Paid
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Account Receivables
Other Cashflows From Investing Activities
Change Receivables
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Property Plant Equipment
Net Tangible Assets
Non Currrent Assets Other
Other Assets
Deferred Long Term Liab
Long Term Investments
Long Term Debt
Net Receivables
Retained Earnings Total Equity
Capital Surpluse
Inventory
Intangible Assets
Common Stock
Non Current Liabilities Other
Short Long Term Debt Total
Capital Lease Obligations
Net Invested Capital
Net Working Capital
Short Term Debt
Long Term Debt Total
Current Deferred Revenue
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Total Revenue
Gross Profit
Net Income From Continuing Ops
Cost Of Revenue
Net Income Applicable To Common Shares
Income Tax Expense
Non Operating Income Net Other
Discontinued Operations
Tax Provision
Reconciled Depreciation
Extraordinary Items
Selling And Marketing Expenses
Probability Of Bankruptcy
Understanding current and past Aclaris Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Aclaris Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Aclaris Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Aclaris Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Aclaris Therapeutics. Check Aclaris Therapeutics' Beneish M Score to see the likelihood of Aclaris Therapeutics' management manipulating its earnings.
Aclaris Therapeutics Stock Summary
Aclaris Therapeutics competes with Neogen, Qiagen NV, Sotera Health, RadNet, and Myriad Genetics. Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Aclaris Therapts operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Aclaris Therapeutics Key Income Statement Accounts
The reason investors look at the income statement is to determine what Aclaris Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Aclaris Therapeutics's current stock value. Our valuation model uses many indicators to compare Aclaris Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aclaris Therapeutics competition to find correlations between indicators driving Aclaris Therapeutics's intrinsic value. More Info.
Aclaris Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Aclaris Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Aclaris Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Aclaris Therapeutics Systematic Risk
Aclaris Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Aclaris Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Aclaris Therapeutics correlated with the market. If Beta is less than 0 Aclaris Therapeutics generally moves in the opposite direction as compared to the market. If Aclaris Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Aclaris Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Aclaris Therapeutics is generally in the same direction as the market. If Beta > 1 Aclaris Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Aclaris Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Aclaris Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Aclaris Therapeutics growth as a starting point in their analysis.
Aclaris Therapeutics November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Aclaris Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Aclaris Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Aclaris Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Aclaris Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Aclaris Therapeutics's daily price indicators and compare them against related drivers.
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.